
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. reported an 8% year-over-year growth in EsoGuard test volume during 3Q24, reaching 2,787 tests. The company anticipates improved revenue growth as it processes claims and collects payments, with expectations for accelerated volume growth following increased market coverage from Medicare and other insurers. Additionally, positive results from the ENVET-BE clinical utility study, which highlighted a significant increase in Barrett's esophagus diagnostic yield for EsoGuard, bolster the outlook for rapid revenue growth as the company continues to commercialize its products.
Bears say
Lucid Diagnostics Inc. is facing a deteriorating financial outlook as test volumes experienced a sequential decline of approximately 11%, despite an 8% year-over-year increase, indicating issues with sustained growth and market penetration. Additionally, the company has revised its revenue estimates for 2024 and 2025 downward, reflecting a lack of confidence in future performance amid increasing operating losses, which grew to $11.7 million in the most recent quarter. The prospects for the company's products, EsoGuard and EsoCheck, remain uncertain due to potential obstacles such as slow adoption rates, insurance reimbursement issues, ineffective marketing strategies, and competition from other cancer detection tests.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares